AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.722
+0.032 (4.62%)
At close: Jun 26, 2026, 4:00 PM EDT
0.704
-0.018 (-2.47%)
After-hours: Jun 26, 2026, 8:00 PM EDT
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Robert Bancroft |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | 949 354 6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00791X209 |
| ISIN Number | US00791X2099 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Bancroft | President, Chief Executive Officer and Director |
| Alex Wilson | Chief Legal and Strategy Officer and Corporate Secretary |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| John A. Bencich M.B.A. | Chief Financial Officer |
| Jennifer Sy | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| May 14, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2026 | 10-K | Annual Report |